John Johnson is Director of Xeris Biopharma Holdings, Inc.. Currently has a direct ownership of 890,983 shares of XERS, which is worth approximately $3.05 Million. The most recent transaction as insider was on Jun 05, 2024, when has been sold 50,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 891K
0% 3M change
66.29% 12M change
Total Value Held $3.05 Million

JOHN JOHNSON Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 05 2024
BUY
Grant, award, or other acquisition
-
50,000 Added 5.31%
890,983 Common Stock
Mar 18 2024
BUY
Exercise of conversion of derivative security
$429,044 $1.99 p/Share
215,600 Added 22.3%
751,412 Common Stock
Mar 15 2024
BUY
Other acquisition or disposition
-
89,571 Added 9.63%
840,983 Common Stock
Jun 07 2023
BUY
Grant, award, or other acquisition
-
42,500 Added 7.35%
535,812 Common Stock
Jun 08 2022
BUY
Grant, award, or other acquisition
-
15,000 Added 2.95%
493,312 Common Stock
Oct 05 2021
BUY
Grant, award, or other acquisition
-
478,312 Added 50.0%
478,312 Common Stock

Also insider at

AXGN
Axogen, Inc. Healthcare
VSTM
Verastem, Inc. Healthcare
APLT
Applied Therapeutics Inc. Healthcare
SBBP
Strongbridge Biopharma plc
JJ

John Johnson

Director
Trevose, PA

Track Institutional and Insider Activities on XERS

Follow Xeris Biopharma Holdings, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells XERS shares.

Notify only if

Insider Trading

Get notified when an Xeris Biopharma Holdings, Inc. insider buys or sells XERS shares.

Notify only if

News

Receive news related to Xeris Biopharma Holdings, Inc.

Track Activities on XERS